IMPORTANCE OF IMMUNOLOGICAL FACTORS IN THE DEVELOPMENT OF RETINOPATHY OF PREMATURITY


Cite item

Full Text

Abstract

Retinopathy of prematurity is one of the most severe multifactorial diseases eye deeply in preterm infants is associated with general and local morfofunkcional’noj immaturity and vazoproliferasion, often leading to blindness and low vision project and progressing during the entire life. Our review article focuses on the role of immunolological factors in the development of retinopathy of prematurity. The data obtained and further research to study the role of immunological parameters in the pathogenesis of retinopathy of prematurity and develop, on the basis of this, it caused by correction techniques to prevent the occurrence and progression of the disease remain a burning issue at present.

About the authors

Julia Dmytrievna Kuznetsova

Russian children’s Clinical Hospital Russian Ministry of Health

Email: kuznecovay@mail.ru
«Russian children’s Clinical Hospital Russian Ministry of Health, doctor of oftolmology department, The Highest category doctor, Moscow, 117997 Moscow, 117997, Russian Federation

L. M Balashova

N.I. Pirogov Russian National Research Medical University Ministry of Health

Moscow, 117997, Russian Federation

S. N Bykovskaya

N.I. Pirogov Russian National Research Medical University Ministry of Health

Moscow, 117997, Russian Federation

References

  1. Terry T.L. Fibroblastic overgrowth of persistent tunica vasculosa lentis in infants born prematurely stage 3. Studies in development and regression of hyaloids artery and tunica vasculosa lentis. Am. J. Ophthalmol. 1942; 25: 1409.
  2. Дегтярева М.В., Дегтярев Д.Н., Володин Н.Н., Ковальчук Л.В. Роль интерлейкина-1 и фактора некроза опухолей новорожденных детей в норме и патологии. Педиатрия.1996; (1): 93-7.
  3. Correa-Rocha R., Perez A., Lorente R., Ferrando-Martinez S., Leal M., et al. Preterm neonates show marked leukopenia and lymphopenia that are associated with increased regulatory T-cell values and diminished IL-7. Pediatr. Res. 2012; 71: 590-7
  4. Scheible K.M., Emo J., Yang H. et al. Developmentally determined reduction in CD31 during gestation is associated with CD8+ T cell effector differentiation in preterm infants. Clin. Immunol. 2015 Dec;161(2):65-74.
  5. Siegrist C.A., Aspinall R. B-cell responses to vaccination at the extremes of age. Nat. Rev. Immunol.2009;9:185-94.
  6. Катаргина Л.А. , Слепова О.С., Скрипец П.П. и др. Гуморальный иммунный ответ на S-антиген сетчатки и его роль в развитии и течении ретинопатии недоношенных. Вестн. офтальмол. 2003; ( 1): 20-2.
  7. Hellstrom A., Smith L.E., Dammann O. “Retinopathy of prematurity”. Lancet. 2013 Oct 26;382(9902): 1445-57.
  8. Sonmez K., Drenser K.A., Caoine A.Jr. , et al. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopayhy of prematurity. Ophthalmology. 2008; 115: 1065-70.
  9. Langer H.F., Chung K.J., Orlova V.V. et al. Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood. 2010 Nov 25; 116 (22): 4395-403.
  10. Kurtul B.E., Kabatas E.U., Zenciroglu A., Ozer P.A., Ertugrul G.T., Beken S., Okumus N. Serum neutrophil-to-lymphocyte ratio in retinopathy of prematurity. J AAPOS. 2015 Aug; 19(4):327-31.
  11. Слепова О.С., Катаргина Л.А., Гвоздюк Н.А., Белова М.В. Влияние системной продукции ростовых факторов (VEGF и fIGF-I ) на течение заболевания у детей с ретинопатией недношенных. Рос. офтальмол. журн. 2011; 4(4): 60-4.
  12. Ferguson T.A., Apte R.S. Angiogenesis in eye disease: immunity gained or immunity lost? Semin Immunopathol. 2008; 30(2): 111-9.
  13. Löfqvist C., Hansen-Pupp I., Andersson E., Holm K., Smith L.E., Ley D., Hellström A. Validation of a new retinopathy of prematurity screening method monitoring longitudinal postnatal weight and insulinlike growth factor I. Arch Ophthalmol. 2009;127: 622-7.
  14. Pérez-Muñuzuri A., Fernández-Lorenzo J.R., Couce-Pico M.L., Blanco-Teijeiro M.J., Fraga-Bermúdez J.M. Serum levels of IGF1 are a useful predictor of retinopathy of prematurity. Acta Paediatr. 2010; 99: 519-25.
  15. Pieh C., Krüger M., Lagrèze W.A., Gimpel C., Buschbeck C., Zirrgiebel U., Agostini H.T. Plasma sE-selectin in premature infants: a possible surrogate marker of retinopathy of prematurity. Invest. Ophthalmol. Vis Sci. 2010; 51: 3709-13.
  16. Bhola R., Purkiss T., Hunter S., Stewart D., Rychwalski P.J. Effect of granulocyte colony-stimulating factor on the incidence of threshold retinopathy of prematurity. J AAPOS. 2009; 13: 450-3.
  17. Hellstrom A., Perruzzi C., Ju M. et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity. Proc. Natl Acad. Sci. USA. 2001; 98 (10): 5084-8.
  18. Löfqvist C., Niklasson A., Engström E., Friberg L.E., Camacho-Hübner C., Ley D., Borg J., Smith L.E., Hellström A. A. Pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants. Pediatr Res. 2009;65: 574-9.
  19. Mititelu M., Chaudhary K.M., Lieberman R.M. An evidence-based meta-analysis of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 1. Retinopathy of prematurity. J. Pediatr. Ophthalmol Strabismus. 2012; 49 :332-40.
  20. Сидоренко Е.Е. Использование ингибиторов СЭФР при ретинопатии недоношенных / Иванова Н.М.,Шварова А.В.,Притыко А.Г. В кн.: Тезисы науч.-практ. конф. с междунар. участием «Ретинопатия недоношенных» 2016. Москва; 2016: 127-9.
  21. Darlow B.A., Ells A., Gilbert G.C., Gole G., Quinn G. Are we there yet? Bevacizumab treatment for retinopathy of prematurity. Arch. Dis.Child.Fetal. Neonatal. Ed. Epub, 2011, December 30.
  22. Isaac М., Tehrani N., Mireskandari K. Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up. Eye(Lond).2016Mar;30(3):333-41
  23. Mota A., Carneiro A., Breda J. et al. Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity. Case Rep. Ophthalmol. 2012; 3 ( 1): 136-41.
  24. Hård A.L., Smith L.E., Hellström A. Nutrition, insulin-like growth factor-1 and retinopathy of prematurity. Semin Fetal. Neonatal. Med. 2013:Feb 18.
  25. Ley D., Hansen-Pupp I., Niklasson A., Domellöf M., Friberg L.E., Borg J., Löfqvist C., Hellgren G., Smith L.E., Hård A.L., et al. Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm infants: pharmacokinetics and short-term safety. Pediatr Res. 2013; 73: 68-74.
  26. Sood B.G., Madan A., Saha S., Schendel D., Thorsen P., Skogstrand K., Hougaard D., Shankaran S., Carlo W. Perinatal systemic inflammatory response syndrome and retinopathy of prematurity.NICHD neonatal research network. Pediatr. Res. 2010 Apr;67(4): 394-400.
  27. Chen S.N., Lian I., Hwang Y.C., Chen Y.H., Chang Y.C., Lee K.H., Chuang C.C., Wu W.C. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Retina. 2015; 35: 667-74.
  28. Tufail А. et al. late onset vitreoretinal complications of regressed ROP. Br. J. Ophthalmol. 2004; 88: 243-6.
  29. Azizia M., Lloyd J., Allen M., Klein N., Peebles D. Immune status in very preterm neonates. Pediatrics.2012 Apr;129(4): 967-74.
  30. Dembinski J., Behrendt D., Martini R., Heep A., Bartmann P. Modulation of pro- and anti-inflammatory cytokine production in very preterm infants. Cytokine. 2003; 21: 200-6.
  31. Schultz C., Rott C., Temming P., Schlenke P., Moller J.C., Bucsky P. Enhanced interleukin-6 and interleukin-8 synthesis in term and preterm infants. Pediatr. Res. 2002; 51: 317-22.
  32. Strunk T., Currie A., Richmond P., Simmer K., Burgner D. Innate immunity in human newborn infants: prematurity means more than immaturity. J. Matern. Fetal Neonatal Med. 2011 Jan; 24(1): 25-31.
  33. Алакаева И.Б. Особенности гемопоэза во внутриутробном периоде и влияние на него внутриутробных инфекций. Педиатрия. 2009; (4): 122-5.
  34. Володин Н.Н. Иммунология интранатального периода: проблемы и перспективы. Педиатрия. 2001; 4: 4-8.
  35. Чистякова Г.Н., Чарипова Б.Т., Тарасова М.Н., Билимова С.И., Газиева И.А. Ремизова И.И. Особенности состояния иммунной системы и характер микробной колонизации детей с экстремально низкой массой тела при рождении. Педиатрия.Журнал им.Г.Н.Сперанского.2013; 92( 2): 42-8.
  36. Belderbos M.E., van Bleek G.M., Levy O., Blanken M.O., Houben M.L., Schuijff L, Kimpen J.L., Bont L. Skewed pattern of Toll-like receptor 4-mediated cytokine production in human neonatal blood: Low LPS-induced IL-12p70 and high IL-10 persist throughout the first month of life. Clin. Immunol. 2009; 133: 228-37.
  37. Hartel C., Osthues I., Rupp J., Haase B., Roder K., Gopel W., Herting E., Schultz C. Characterisation of the host inflammatory response to Staphylococcus epidermidis in neonatal whole blood. Arch Dis Child Fetal Neonatal Ed. 2008; 93: 140-5.
  38. Schultz C., Temming P., Bucsky P., Gopel W., Strunk T., Hartel C. Immature anti-inflammatory response in neonates. Clin. Exp. Immunol. 2004;135: 130-6.
  39. Tatad A.M., Nesin M., Peoples J., Cheung S., Lin H., Sison C., Perlman J., Cunningham-Rundles S. Cytokine expression in response to bacterial antigens in preterm and term infant cord blood monocytes. Neonatology. 2008; 94: 8-15.
  40. Катаргина Л.А., Слепова О.С., Белова М.В., Андрюшин А.Е.Значение нарушений цитокинового статуса в патогенезе поздних витреоретинальных осложнений ретинопатии недоношенных. Рос. педиатр. офтальмол. 2013; (2): 14-7.
  41. Катаргина Л.А. , Коголева Л.В., Белова М.В., Денисова Е.В. Поздние отслойки сетчатки при ретинопатии недоношенных. Офтальмохирургия. 2009; (3): 31-4.
  42. Mutlu F.M., Sarici S.U. Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options. Int. J. Ophthalmol. 2013; 6: 228-36.
  43. Kojima H., Otani A., Oishi A., Makiyama Y., Nakagawa S., Yoshimura N. Granulocyte colony-stimulating factor attenuates oxidative stress-induced apoptosis in vascular endothelial cells and exhibits functional and morphologic protective effect in oxygen-induced retinopathy. Blood. 2011; 117: 1091-100.
  44. Sato T., Kusaka S., Shimojo H., Fujikado T. Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmology. 2009; 116: 2165-9.
  45. Connor K.M., SanGiovanni J.P., Lofqvist C., Aderman C.M., Chen J., Higuchi A., Hong S., Pravda E.A., Majchrzak S., Carper D., et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat.Med. 2007; 13: 868-73.
  46. Hunt S. Increased dietary intake of omega-3-PUFA reduces pathological retinal angiogenesis. Ophthalmology. 2007; 104: 727-9.
  47. Stahl A., Sapieha P., Connor K.M., Sangiovanni J.P., Chen J., Aderman C.M., Willett K.L., Krah N.M., Dennison R.J., Seaward M.R., et al. Short communication: PPAR gamma mediates a direct antiangiogenic effect of omega 3-PUFAs in proliferative retinopathy. Circ. Res. 2010; 107: 495-500.
  48. Flor-de-Lima F., Rocha G., Proença E., Tafulo S., Freitas F., Guimarães H. The role of the human leukocyte antigen system in retinopathy of prematurity: a pilot study. 2013 Dec;102(12): 1150-3.
  49. Балашова Л.М., Быковская С.Н., Кузнецова Ю.Д., Коробова Л.С. Количественные и функциональные нарушения показателей клеточного иммунитета у взрослых, пожилых людей, соматически здоровых детей и больных ретинопатией недоношенных. Клин. геронтол. 2012; 18(11-12): 76-7.

Copyright (c) 2018 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies